Drug Profile
Research programme: CNS iron chelators - BTG
Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator Kings College London
- Developer BTG
- Class
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Parkinson's disease
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 04 May 2004 Preclinical trials in Alzheimer's disease in United Kingdom (unspecified route)
- 04 May 2004 Preclinical trials in Parkinson's disease in United Kingdom (unspecified route)